Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd. OXNARD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet...

Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders OXNARD, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology announced today that it has entered into a product...

CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids OXNARD, Calif. and TEL AVIV, Israel, July 11, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid...